GlassScriptPhysician profile
Rim Tabbaa
NPI 1467686717
$12,453.32
in general payments reported to CMS, 2019-2025
52 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $1,549 · 2021: $2,213 · 2022: $2,020 · 2023: $1,881 · 2024: $2,265 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,581.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,359.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,034.81 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $979.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $933.48 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $794.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $739.87 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $659.47 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $581.09 | 2019-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $557.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $494.91 | 2022-2025 | |
| Amgen INC. | $469.05 | 2019-2025 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $446.71 | 2019-2023 | Veozah |
| Abbott Laboratories | $444.25 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $390.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $288.54 | 2019-2025 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rim Tabbaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.